Crystal's Coder Hub🔱 CPT 52240 — Cystourethroscopy With Fulguration and/or Resection of Large Bladder Tumor(s)
Quick Reference
wRVU: 10.30 | Global Period: 090 (90 days) | Assistant Payable: ✅ Yes | Bilateral Indicator: 3
📋 Clinical Description
CPT 52240 describes the transurethral endoscopic treatment of one or more LARGE bladder tumors (greater than 5.0 cm) using a cystoscope passed through the urethra, with fulguration (electrocautery, cryosurgery, or laser ablation) and/or resection (loopresection using a resectoscope). The operative approach is entirely endoscopic — no external incision is made. This code sits at the top of the size-stratified bladder tumor fulguration/resection family and is selected based exclusively on tumor size: use 52234 for small tumors (0.5 up to 2.0 cm), 52235 for medium (2.0 to 5.0 cm), and 52240 when the tumor exceeds 5.0 cm. The operative note must document tumor size or clearly support “large” classification for this code to survive audit.
Bladder cancer (malignant neoplasm of the bladder — C67.x series) is the most common diagnosis driving this code; transitional cell (urothelial) carcinoma accounts for the vast majority of cases. Carcinoma in situ (D09.0) and neoplasms of uncertain behavior (D41.4) may also drive this code. When a tumor is first identified, this procedure serves as both diagnostic and therapeutic — tissue removed via resection is sent to pathology, and the histologic result drives subsequent ICD-10-CM coding specificity for future encounters.
This procedure may be performed in the following clinical contexts:
- Initial TURBT (Transurethral Resection of Bladder Tumor) for Suspected Malignancy — First-time resection of a newly identified large bladder mass, with specimen submission for histologic staging
- Recurrent Bladder Tumor — Large or Progressive — Previously treated tumor that has recurred or grown to large size on surveillance cystoscopy, requiring more aggressive resection
- Debulking Prior to Intravesical Therapy — Large tumor debulked transurethally before BCG (Bacillus Calmette-Guérin) or chemotherapy instillation
- Fulguration Only for Superficial Large Lesion — When the surgeon elects destruction without excision due to tumor characteristics, comorbidity, or bleeding risk; fulguration alone (laser or electrocautery) is captured under this same code
- Palliative Resection in Advanced Disease — Large tumor resected endoscopically for hemorrhage control or symptom management in patients with advanced disease where curative resection is not the primary goal
🔬 Anatomical & Procedural Considerations
| Modality | Mechanism / Steps | Key Notes / Coding Impact |
|---|---|---|
| Monopolar/Bipolar Electrocautery Resection (Standard TURBT) | Resectoscope loop excises tumor in successive chips; electrocoagulation controls bleeding; chips are evacuated for pathology | Most common approach; bipolar preferred in patients with pacemakers/ICDs; document tumor size and technique |
| Laser Fulguration (Holmium, Nd:YAG, GreenLight) | Laser energy ablates/vaporizes tumor tissue directly; coagulates surrounding mucosa | Tissue may not be recoverable for pathology if pure vaporization used — document whether tissue was sent; laser type should be noted but does not change CPT selection |
| Cryosurgery | Cryoprobe applied via cystoscope freezes and destroys tumor cells | Less commonly used for bladder tumors; acceptable technique under this code descriptor; document clearly |
| Combination (Resection + Fulguration) | Bulk tumor resected, base and margins fulgurated to ensure complete destruction of the tumor bed | Standard of care for complete TURBT; “fulguration and/or resection” language in descriptor accommodates this combined approach under one code |
Clinical Pearl
The single most important documentation element for 52240 is tumor size — the operative report must state or clearly support “large” (>5.0 cm) to differentiate from 52235 (medium). When size is not explicitly stated, coders should query before defaulting to a lower-level code. Additionally, intravesical instillation of BCG or chemotherapy (51720) performed immediately post-resection in the same OR session is bundled and NOT separately reportable; it is only separately billable if performed in a distinct session (e.g., recovery room, same day separate encounter) with modifier -59 appended to 51720.
✅ Procedure Includes
- Pre-procedure cystoscopic inspection of the entire bladder and urethra
- General, regional (spinal/epidural), or IV sedation anesthesia (separately billed by anesthesia provider)
- Transurethral insertion and manipulation of the cystoscope/resectoscope
- Fulguration and/or resection of the bladder tumor(s)
- Evacuation of resected tissue chips for pathologic submission
- Intraoperative hemostasis and bleeding control (electrocoagulation of the resection bed)
- Post-procedure bladder irrigation as part of the operative session
- Documentation of tumor location, size, number, and technique in the operative report
❌ Excludes / Do Not Report Together
| Code | Description | Relationship to 52240 |
|---|---|---|
| 52235 | Cystourethroscopy with fulguration/resection of MEDIUM bladder tumor(s) (2.0-5.0 cm) | Mutually exclusive by tumor size — report 52240 OR 52235, never both; selection determined solely by documented tumor size |
| 52234 | Cystourethroscopy with fulguration/resection of SMALL bladder tumor(s) (0.5-2.0 cm) | Mutually exclusive by tumor size; if multiple tumors of different sizes are treated, report the single highest-level code reflecting the largest tumor treated |
| 52000 | Cystourethroscopy (separate procedure) | Bundled — diagnostic cystoscopy is a component of 52240; do not report separately |
| 52204 | Cystourethroscopy with biopsy(s) | Cold-cup biopsies of the tumor or surrounding mucosa are bundled into 52240; not separately reportable in the same session at the same site |
| 51720 | Bladder instillation of anticarcinogenic agent | Bundled if performed in the OR immediately following 52240 in the same session; separately reportable with modifier -59 on 51720 only if performed as a distinct, separate encounter on the same date |
| E/M codes (992xx / 920xx) | Office visit, any level | Separately reportable only when modifier -25 is appended to the E/M code, documenting a significant, separately identifiable E/M service beyond the routine pre-procedure assessment |
Bundling Alert — Global Period is 090, Not 000 or 010
52240 carries a 90-day global period, meaning all routine follow-up care, post-operative visits, and related services within 90 days of the procedure date are bundled into the surgical payment — no separate E/M billing without modifier -24 (unrelated E/M during global period) or -79 (unrelated procedure during global period). The most common audit finding is billing E/M visits within the 90-day window without supporting documentation that the visit was for an unrelated condition. For unrelated visits, append modifier -24 to the E/M code and document explicitly in the note that the visit was unrelated to the procedure and global period — e.g., “This visit is unrelated to the patient’s TURBT performed on [date] and addresses [unrelated condition].”
🌳 Code Tree — Surgery: Urinary System (Endoscopy: Bladder)
CPT 52000-52356 Surgery: Urinary System — Cystourethroscopy
│
├── 52000 Cystourethroscopy (separate procedure) (Global: 000)
│
├── 52204-52240 Cystourethroscopy with Fulguration/Resection
│ ├── 52204 Cystourethroscopy with biopsy(s) (Global: 000)
│ ├── 52224 Cystourethroscopy with fulguration/treatment of MINOR lesion(s) <0.5 cm (Global: 000)
│ ├── 52234 Cystourethroscopy with fulguration/resection of SMALL tumor(s) (0.5-2.0 cm) (Global: 090)
│ ├── 52235 Cystourethroscopy with fulguration/resection of MEDIUM tumor(s) (2.0-5.0 cm) (Global: 090)
│ ├── ▶▶ 52240 ◀◀ Cystourethroscopy with fulguration/resection of LARGE tumor(s) ← YOU ARE HERE (Global: 090)
│ └── 52250 Cystourethroscopy with insertion of radioactive substance (Global: 090)
│
└── 52260-52356 Additional Cystourethroscopic Procedures
├── 52260 Cystourethroscopy with dilation for interstitial cystitis; general anesthesia
└── 52332 Cystourethroscopy with insertion of indwelling ureteral stent
💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU (wRVU) | 10.30 (2026 CMS MPFS; reflects -2.5% efficiency adjustment finalized in CY2026 PFS Final Rule CMS-1832-F) |
| Global Period | 090 (90 days) |
| Bilateral Indicator | 3 — procedure not subject to bilateral reduction rules; bladder is a single unpaired organ |
| Assistant Surgeon | ✅ Payable |
| Co-Surgeon | ❌ Not applicable |
| Team Surgery | ❌ Not applicable |
| PC/TC Split | ❌ No — procedure code only (Indicator 0) |
| Modifier -51 Exempt | No |
| Anesthesia | General, regional (spinal/epidural), or IV sedation — billed separately by anesthesia provider; not included in 52240 payment |
| 2026 MD In-Facility Medicare Allowed Amount | $344 (national unadjusted average) |
| 2026 Hospital Outpatient APC | 5375 — Medicare Allowed Amount $5,478 |
| 2026 ASC Medicare Allowed Amount | $2,730 |
Bilateral Billing Rules
52240 has a bilateral indicator of 3, meaning the bladder is a single, unpaired organ and bilateral reduction rules do not apply. There is no bilateral billing scenario for this code — it is reported once regardless of how many tumors are treated or what portion of the bladder is involved in a single session.
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -51 | Multiple Procedures | When 52240 is performed alongside other surgical procedures in the same operative session; apply -51 to the lower-valued code |
| -59 | Distinct Procedural Service | When a payer incorrectly bundles 52240 with a separately reportable service (e.g., 51720 in a distinct encounter same day); documents distinct procedural service |
| -52 | Reduced Services | Procedure partially completed — document specific reason (e.g., patient tolerance, bleeding, inadequate visualization) |
| -53 | Discontinued Procedure | Procedure stopped after initiation due to patient safety concerns; document reason thoroughly in operative/procedure note |
| -58 | Staged or Related Procedure | Planned staged re-resection during the 90-day global period (e.g., second-look TURBT) — append to the subsequent procedure CPT code |
| -78 | Unplanned Return to OR | Unplanned return for complication (e.g., hemorrhage) during the 90-day global period |
| -79 | Unrelated Procedure During Postoperative Period | Unrelated surgical procedure performed during the 90-day global window |
| -24 | Unrelated E/M During Postoperative Period | Applied to the E/M code when patient is seen within the 90-day global window for a condition unrelated to the TURBT |
| -25 | Significant, Separately Identifiable E/M | Applied to the E/M code — not to 52240 — when an office visit on the same day involves a separately documented, medically necessary evaluation beyond the pre-procedure assessment |
🩺 Common ICD-10-CM Pairings
Malignant Neoplasm of Bladder — Primary
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| C67.0 | Malignant neoplasm of trigone of bladder | ✅ HCC 12 | Use when tumor location is specifically documented as the trigone |
| C67.1 | Malignant neoplasm of dome of bladder | ✅ HCC 12 | Use when dome location is documented |
| C67.2 | Malignant neoplasm of lateral wall of bladder | ✅ HCC 12 | Most common location for urothelial carcinoma; use when lateral wall is documented |
| C67.3 | Malignant neoplasm of anterior wall of bladder | ✅ HCC 12 | Use when anterior wall is specified |
| C67.4 | Malignant neoplasm of posterior wall of bladder | ✅ HCC 12 | Use when posterior wall is specified |
| C67.5 | Malignant neoplasm of bladder neck | ✅ HCC 12 | Use when bladder neck involvement is documented |
| C67.6 | Malignant neoplasm of ureteric orifice | ✅ HCC 12 | Use when tumor involves the ureteric orifice |
| C67.9 | Malignant neoplasm of bladder, unspecified | ✅ HCC 12 | Use only when tumor site within the bladder is entirely undocumented; query provider for site specificity when possible |
Noninvasive / In Situ / Uncertain Behavior
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| D09.0 | Carcinoma in situ of bladder | ❌ No | Use when pathology confirms CIS without invasive component; distinct from C67.x — do not upcode without pathologic confirmation |
| D41.4 | Neoplasm of uncertain behavior of bladder | ❌ No | Use pre-pathology when neoplasm is unconfirmed as benign or malignant; do not use once pathologic staging is available |
Secondary / Complication Codes
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| R31.0 | Gross hematuria | ❌ No | Report as additional diagnosis when hematuria is the presenting symptom driving the procedure; not a substitute for the neoplasm code |
| N30.41 | Irradiation cystitis with hematuria | ❌ No | Report as additional diagnosis when prior pelvic radiation is documented as contributing to the clinical picture |
Coding Specificity Reminder
The ICD-10-CM C67.x series requires documentation of the specific anatomic site within the bladder. The operative report and/or the pathology report are the primary sources for site specificity. If the surgeon documents only “bladder tumor” without a specific wall or location, query for the precise site before defaulting to C67.9. ICD-10-CM specificity requirements are not optional — payers including Medicare and its MACs increasingly flag claims with C67.9 when operative documentation would support a more specific code.
🏥 MS-DRG Considerations (Inpatient)
Inpatient Coding Reminder
CPT 52240 is performed primarily in the outpatient hospital or ASC setting, but inpatient admissions do occur for large, complex tumors, hemorrhage management, or patient comorbidity. When 52240 drives an inpatient admission, it maps to MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract). With a principal diagnosis of bladder malignancy (C67.x), the DRG family is 668 / 669 / 670 (Transurethral Procedures with MCC / CC / without CC/MCC). With a neoplasm-driven admission, mapping may alternatively fall to DRG 656 / 657 / 658 (Kidney and Ureter Procedures for Neoplasm). CC/MCC tier selection is critical — document all comorbidities and complications (e.g., hematuria with anemia, urinary obstruction, prior radiation) to support appropriate DRG assignment.
🔧 ICD-10-PCS Equivalents (Inpatient Facility Coding)
Note
For inpatient admissions where 52240 is performed, ICD-10-PCS coding is required in place of CPT. Two root operations are applicable depending on the technique: Destruction (5) is used when fulguration/ablation is the primary action (no tissue removed for pathology); Extirpation (C) is used when resection of tumor matter from the bladder wall is the primary action. When both resection and fulguration are performed, Extirpation is the preferred root operation. These PCS codes will influence DRG grouping under MDC 11.
| PCS Code | Full Description | Applicable Modality |
|---|---|---|
0TBC8ZZ | Medical and Surgical — Urinary System — Extirpation — Bladder — Via Natural or Artificial Opening Endoscopic — No Device — No Qualifier | Resection (TURBT) approach; tissue removed |
0T5B8ZZ | Medical and Surgical — Urinary System — Destruction — Bladder — Via Natural or Artificial Opening Endoscopic — No Device — No Qualifier | Fulguration/ablation approach; tissue not excised |
PCS Character Analysis — 0TBC8ZZ
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical |
| 2 | Body System | T | Urinary System |
| 3 | Root Operation | C | Extirpation (taking or cutting out solid matter from a body part) |
| 4 | Body Part | B | Bladder |
| 5 | Approach | 8 | Via Natural or Artificial Opening Endoscopic |
| 6 | Device | Z | No Device |
| 7 | Qualifier | Z | No Qualifier |
PCS Root Operation: Extirpation (C) vs. Destruction (5)
- Use Extirpation (C) when the primary operative action is resection — the tumor mass is physically removed and tissue is sent for pathologic analysis
- Use Destruction (5) when the primary operative action is fulguration/ablation — tumor tissue is destroyed in situ without excision (e.g., laser vaporization where no tissue is recovered)
- When both techniques are used in the same session (resection + fulguration of the base), assign Extirpation as the root operation — the more definitive action governs PCS code selection per the ICD-10-PCS Official Guidelines
📝 Coding Examples
Example 1 — Outpatient Hospital: Initial TURBT for Large Bladder Mass, Lateral Wall
Clinical Scenario: A 68-year-old male with gross hematuria underwent cystoscopy revealing a large (approximately 6.5 cm) sessile mass on the left lateral wall of the bladder. The urologist performed transurethral resection using a bipolar resectoscope, resecting the tumor in multiple chips with electrofulguration of the base and margins. Tissue was submitted to pathology. The operative note documents “large bladder tumor, left lateral wall, approximately 6.5 cm, resected with bipolar TURBT technique; fulguration of base performed.” Pathology confirmed high-grade urothelial carcinoma. No separate E/M was performed.
| Field | Code | Rationale |
|---|---|---|
| CPT | 52240 | Large bladder tumor (>5.0 cm documented at 6.5 cm); resection with fulguration; transurethral endoscopic approach |
| PDx | C67.2 | Malignant neoplasm of lateral wall of bladder — most specific site code supported by operative and pathology documentation |
| SDx | R31.0 | Gross hematuria — presenting symptom documented in H&P; report as additional diagnosis |
Note
No modifier -25 is applicable here as no separately documented E/M was performed. The 90-day global period begins on the date of service — flag the date in your practice management system and block related follow-up visits from separate E/M billing through the global end date.
Example 2 — Outpatient Hospital: Large Bladder Tumor with Same-Day Pre-Op E/M
Clinical Scenario: A 72-year-old female was seen in the office for a new patient evaluation for gross hematuria. The physician performed a comprehensive history and physical, reviewed imaging, and identified a suspected large bladder lesion. A decision was made to schedule TURBT; however, due to the patient’s presentation, the procedure was performed the same day in the outpatient surgical suite. The physician documented a separate, detailed new patient E/M with independent medical decision-making beyond the pre-procedure assessment. The operative report documents resection of a 7 cm bladder dome tumor.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 99205-25 | New patient E/M, high complexity MDM — modifier -25 on the E/M code, documenting a significant separately identifiable service beyond the routine pre-procedure assessment |
| CPT 2 | 52240 | Large bladder tumor (7 cm dome) — resection performed same day |
| PDx | C67.1 | Malignant neoplasm of dome of bladder — site documented in operative report |
| SDx | R31.0 | Gross hematuria — presenting symptom driving the evaluation |
Warning
Modifier -25 belongs on the E/M code (99205), NOT on the procedure code (52240). This is one of the most common modifier misplacement errors in urology billing. The E/M documentation must stand completely independently — it cannot simply restate the pre-procedure assessment. The note must reflect a medically necessary, separately identifiable evaluation with its own HPI, exam findings, and decision-making.
Example 3 — Inpatient: Staged Re-Resection During Global Period (Second-Look TURBT)
Clinical Scenario: A 65-year-old male underwent initial TURBT (52240) for a large high-grade urothelial carcinoma of the posterior bladder wall on [Date 1]. The urologist planned a second-look TURBT at 4-6 weeks per standard of care for muscle-invasive disease staging. The patient was re-admitted at 5 weeks post-op for the staged re-resection. The operative note documents “second-look TURBT, planned staged procedure per NCCN guidelines, original TURBT performed [Date 1].”
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 52240-58 | Same procedure — 52240; modifier -58 designates this as a planned staged procedure during the 90-day global period of the original 52240 |
| PDx | C67.4 | Malignant neoplasm of posterior wall of bladder — site consistent with original procedure and current operative documentation |
Note
Global period reminder: Modifier -58 is required when a staged, related procedure is performed during the global period of a prior procedure. Without -58, the second procedure will be denied as bundled within the global payment. Documentation must clearly identify this as a planned staged procedure and reference the original procedure date. The 90-day global period resets with the new procedure date when -58 is appended.
⚠️ Common Coding Pitfalls
-
Missing tumor size documentation: The entire size-stratified family (52234 / 52235 / 52240) depends on documented tumor size. If the operative note says “large tumor” without a measurement, you are on thin ice — “large” is a qualitative descriptor that will hold up better if corroborated by a measurement. When no size is documented, query the urologist before billing 52240; without supporting documentation, the claim will be downcoded to 52235 or even 52234 on audit.
-
Billing 52240 and 52235 together for multiple tumors of different sizes: When a single session involves multiple tumors of varying sizes, you report only ONE code from the size-stratified family — the code that reflects the largest tumor treated. You cannot bill 52240 + 52235 in the same session. Multiple tumors at the same operative session are captured under a single unit of service.
-
Bundling 51720 into 52240 when it is actually separately reportable: Intravesical instillation performed in the OR immediately after TURBT is bundled. However, if the instillation was performed later in the day (recovery room, patient’s hospital room, a distinct clinical encounter), it IS separately reportable with modifier -59 on 51720. Read the op note AND the recovery room/nursing notes before making this call.
-
Failing to track the 90-day global period: 52240 carries a 90-day global — not a 10-day global. This is longer than many coders assume for endoscopic procedures. All post-op visits related to the TURBT for 90 days are bundled. Use your practice management system to flag the procedure date and global end date on every claim. Failure to track results in overpayments and recoupment liability.
-
Using C67.9 when the operative report documents a specific site: Urologists typically document the anatomic site of the tumor in the operative report. Defaulting to C67.9 (unspecified) without querying is a specificity failure that can trigger medical necessity denials and RAC/MAC audit flags. Always cross-reference the operative note and pathology report before assigning the unspecified code.
-
Incorrect modifier placement for same-day E/M: Modifier -25 goes on the E/M code — never on 52240 itself. Placing -25 on the procedure code will result in a claim denial or processing error. The E/M must be fully documented as a separate, medically necessary service independent of the pre-procedure assessment.
📎 Sources
1. AMA CPT 2026 Professional Edition — Surgery: Urinary System, Cystourethroscopy, codes 52234-52240 · 2. CMS CY 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), released October 2025; Addendum B RVU file · 3. Boston Scientific 2026 Coding and Payment Guide — Cystoscopy-Based Procedures (effective 1JAN2026) · 4. CMS FY 2026 IPPS Final Rule (CMS-1833-IFC); MS-DRG v43.0 Grouper — MDC 11, DRG 668-670 · 5. ICD-10-CM Official Guidelines for Coding and Reporting FY2026 — Chapter 2 (Neoplasms) · 6. ICD-10-PCS Official Guidelines for Coding and Reporting FY2026 — Root Operation Selection, Extirpation vs. Destruction · 7. AAPC Urology Coding Alert — “TURBT Size Stratification and Bundling Rules” (2024) · 8. NCCI Policy Manual Chapter 7 (Urinary System), CMS 2025-2026 · 9. AUA Coding Tips and Tricks — Medicare Proposed Rule for 2026, AUA News September 2025